MERIL Announces Successful Primary Outcomes of Next-Gen Myval THV Series in Major RCT, Presented at EuroPCR 2024 - Earns Prestigious Late Breaking Trial Status & The LANCET Acceptance

Contributed by: PR Newswire

Tags

Meril-THV-EuroPCR2024

More Like This

PR Newswire associated0

Meril Presents Successful LANDMARK RCT One-Year Results at Prestigious EuroPCR 2025

PR Newswire associated0

Meril Life Sciences Presents One-year Outcomes from the LANDMARK Randomized Controlled Trial at PCR London Valves 2025

PR Newswire associated0

Meril Champions Innovation with Myval Octapro THV Launch at GISE 2024 & PCR LondonValves 2024

PR Newswire associated0

Cardiovalve Submits CE File for Approval Following Successful TARGET Study Completion

The 1-Year Follow-up Results of LuX-Valve Plus were Officially Released at TCT 2024

Cardiovalve Completes TARGET Study Enrollment for CE Registration Study for Tricuspid Valve Replacement

PR Newswire associated0

First Implant of KingstronBio's ProStyle M® Transcatheter Mitral Valve System Successfully Completed in National Multicenter Confirmatory Study

Venus Medtech's Exciting Innovations for Structural Heart to Be Showcased at London Valves 2023